BioLife Solutions, Inc. (BLFS) FY2026 YTD Q2 P&L / Income Statement

BioLife Solutions, Inc. (BLFS) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

55,966,000 US dollars

Cost of revenue

20,182,000 US dollars

Gross profit

35,784,000 US dollars

Operating expenses (calculated)

34,059,000 US dollars

Operating income (loss)

1,725,000 US dollars

Total other income, net

2,277,000 US dollars

Income (loss) before income tax (benefit) expense

4,002,000 US dollars

Income tax (benefit) expense

negative 42,288,000 US dollars

Net income (loss)

46,290,000 US dollars

Other (calculated)

3,357,960 US dollars

UNITED STATES (calculated)

44,772,800 US dollars

Europe, Middle East, Africa (EMEA) (calculated)

7,835,240 US dollars

General and administrative

22,901,000 US dollars

Research and development

5,608,000 US dollars

IPR&D expense

0 US dollars

Intangible asset amortization

242,000 US dollars

Sales and marketing

5,308,000 US dollars

Loss from discontinued operations

0 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.